Momenta Phama (MNTA) Reports Q3 Loss of $0.44/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 8:05 AM EDT-- Ended third quarter with a strong cash position of $423M --
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2017 and provided a corporate update.
We continue to believe in the potential for the approval and launch of Glatopa® 40 mg in late 2017 or early 2018 and that there remains a meaningful market opportunity for this product in the U.S., said Craig A. Wheeler, President and Chief Executive Officer of Momenta... More
